6131 POSTER Evaluation of BRAF Mutational Status in Wild Type (WT) KRAS Metastatic Colon-Rectal Cancer (MCRC) Patients (pts) Treated With Cetuximab (C) – a Single Institution Experience

Autor:	M.E. Cazzaniqa, G. Bovo, D. Pellizzoni, F. Crosti, S. Baronchelli, F. Villa, Paolo Bidoli, Diego Cortinovis, N. Giuntini
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty Cetuximab business.industry Wild type medicine.disease_cause Internal medicine medicine Colon rectal cancer Mutational status KRAS Single institution business medicine.drug
Zdroj:	European Journal of Cancer. 47:S431
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(11)71776-2
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e97f1f01f399a7d0eba59052018b3692 https://doi.org/10.1016/s0959-8049(11)71776-2 Zobrazit plný text záznamu Full Text from ScienceDirect